Fig. 3

Tumorous IRE1α-XBP1 axis activates CD8⁺T cell-dependent anti-tumor immunity and mediates the tumor-suppressive role of HA15. A, E Schematic of the treatment in C57BL/6 mice bearing with sh-NC-B16F10, sh-IRE1α-B16F10 or sh-XBP1-B16F10 tumors with or without HA15 treatment as indicated. B, F Images of isolated tumors from mice that received indicated treatment. Tumor weights and volumes in each group were calculated and displayed in C, G and D, H. I-J Representative flow cytometry data and summary plots of the frequency of CD8⁺ in tumor from xenografts with indicated treatment. Symbols of one dot indicates one mouse, and the error bars are mean with ± S.D (n = 4). Two-tailed Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001)